Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Multi-targeted tyrosine kinase inhibitors (TKIs) are standard treatments for advanced renal cell carcinoma (RCC), improving patient survival and quality of life.
• TKIs targeting the vascular endothelial growth factor receptor can cause serious adverse events, though acute pancreatitis is rare.
• Pazopanib is a TKI used in RCC treatment, with potential for various side effects.

Purpose of the Study:

• To report the first case of asymptomatic radiological acute pancreatitis in a renal cell carcinoma patient treated with pazopanib monotherapy.
• To conduct a comprehensive literature review on TKI-induced acute pancreatitis in RCC patients.
• To discuss potential strategies for early diagnosis and management of this adverse event.

Main Methods:

• Case report of a patient with advanced RCC.
• Administration of pazopanib as monotherapy.
• Radiological diagnosis of acute pancreatitis.
• Comprehensive literature search on pazopanib and acute pancreatitis in RCC.

Main Results:

• The study presents a unique case of asymptomatic acute pancreatitis, identified radiologically, in an RCC patient on pazopanib.
• Literature review indicates that acute pancreatitis is a rare but potential adverse effect of TKIs in RCC.
• Early detection and management strategies are crucial for mitigating risks associated with TKI-induced pancreatitis.

Conclusions:

• Pazopanib, while effective for RCC, can rarely cause asymptomatic acute pancreatitis.
• Clinicians should be vigilant for pancreatitis as a potential TKI side effect, even in asymptomatic cases.
• Further research and established guidelines are needed for optimal management of TKI-induced pancreatitis in RCC patients.